Gilead and Kite nab an­oth­er ap­proval for Tecar­tus, as lead­ing CAR-T port­fo­lio con­tin­ues to grow

Gilead and Kite took an­oth­er step Fri­day to­ward ex­pand­ing their fran­chise of CAR-T drugs, nab­bing a new ap­proval for Tecar­tus.

The FDA OK’ed the ther­a­py for adults with re­lapsed or re­frac­to­ry B-cell pre­cur­sor acute lym­phoblas­tic leukemia, Gilead an­nounced Fri­day. It’s the drug’s sec­ond in­di­ca­tion af­ter Gilead ini­tial­ly launched the CAR-T in 2020 for adults with re­lapsed or re­frac­to­ry man­tle cell lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER